Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog - TheStreet

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.
5/25/17 11:18AM
An FDA advisory panel is reviewing Puma's breast cancer drug neratinib.
5/24/17 7:41AM
The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring.
5/22/17 10:41AM
Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.S. approval in April for a competing osteoporosis drug, Tymlos.
5/22/17 9:44AM
LJPC-501 reversed dangerously low blood pressure in patients suffering from a severe form of shock, but the drug did not improve total organ function or reduce mortality.
5/22/17 7:13AM
The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.
5/18/17 1:03PM
The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.
5/17/17 5:10PM
The new Merck survival data were included in a research abstract for next month's American Society of Clinical Oncology (ASCO) annual meeting that was distributed on Wednesday night.
5/17/17 5:05PM
The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
5/17/17 5:02PM
Monday's licensing deal is a nice win for Akebia because Fresenius is the largest dialysis provider in North America, serving approximately 40% of dialysis patients in the U.S.
5/15/17 4:05PM
The clinical trial shutdown ordered by regulators in its own country casts another shadow of doubt over AB Science at a most inopportune time.
5/12/17 8:29AM
XBiotech offered no reason for Thornburg's resignation, but he left two weeks after European regulators issued a preliminary recommendation to reject the application for the company's colon cancer drug Xilonix.
5/11/17 8:31AM
Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.
5/10/17 5:29PM
Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?
5/10/17 4:02PM
A presentation on May 18 will shed more light on the efficacy and safety of AB Science's ALS drug masitinib.
5/9/17 8:26AM
The death rattled Kite investors because death from brain swelling, or cerebral edema, is the same severe toxic event that scuttled a competing CAR-T therapy from Juno Therapeutics.
5/8/17 10:06AM
The FDA wants 12-month endometrial safety data on TX-004HR. TherapeuticsMD conducted a single study that lasted just 12 weeks.
5/8/17 9:14AM
The surprise exit of Puma's regulatory chief is sparking fears the FDA will deal harshly with the company's breast cancer drug neratinib.
5/5/17 6:53AM
Zafgen is disclosing Thursday evening the first human data on ZGN-1061, with plans to move the obesity drug into a phase II study.
5/4/17 4:05PM
Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.
5/4/17 1:29PM
Gilead's first-quarter conference call delivered another opportunity for analysts to ask management, 'Who are you going to buy and when?'
5/3/17 6:47PM
Sharon di Stefano loves Neurotrope but doesn't know how her Seeking Alpha articles are being transformed into stock-promoting press releases.
5/3/17 2:58PM
Today's Intra-Cellular update was probably going to send the stock price falling regardless of how management acted, but the refusal to be transparent made a bad day even worse.
5/1/17 11:22AM
Bryostatin failed to produce a meaningful improvement in dementia, cognition or memory of Alzheimer's patients.
5/1/17 7:18AM